Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with GX vs GP in First-line R/M NPC
NCT06177301Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 3 years. Started Dec 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06177301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177301.